Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative
second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth
salts are not available. The investigators compare the efficacies of 10-day
levofloxacin-based sequential therapy and 10-day triple therapy in the treatment for patients
after failure of standard triple therapy and to determine what clinical and bacterial factors
influencing the efficacy of salvage regimens.